MCK outlook supported by Q1 growth and $2.25B Precision acquisition
MCK said strategic focus on oncology and supply chain, including its $2.25B Precision Medicine Group acquisition, supports a positive outlook alongside robust Q1 growth, AI and technology investments, and biosimilar opportunities.